These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 35908242)

  • 21. Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.
    Luigetti M; Antonini G; Di Paolantonio A; Gentile L; Grandis M; Leonardi L; Lozza A; Manganelli F; Mazzeo A; Mussinelli R; My F; Obici L; Maria Pennisi E; Romozzi M; Russo M; Sabatelli M; Salvalaggio A; Tagliapietra M; Tozza S
    Eur J Neurol; 2022 Jul; 29(7):2148-2155. PubMed ID: 35289020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
    Conceição I
    Clin Auton Res; 2019 Sep; 29(Suppl 1):11-17. PubMed ID: 31399774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
    Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
    Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
    Adams D; Tournev IL; Taylor MS; Coelho T; Planté-Bordeneuve V; Berk JL; González-Duarte A; Gillmore JD; Low SC; Sekijima Y; Obici L; Chen C; Badri P; Arum SM; Vest J; Polydefkis M;
    Amyloid; 2023 Mar; 30(1):1-9. PubMed ID: 35875890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.
    Waddington-Cruz M; Ackermann EJ; Polydefkis M; Heitner SB; Dyck PJ; Barroso FA; Wang AK; Berk JL; Dyck PJB; Monia BP; Hughes SG; Tai L; Jesse Kwoh T; Jung SW; Coelho T; Benson MD; Gertz MA
    Amyloid; 2018 Sep; 25(3):180-188. PubMed ID: 30169969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis.
    Dyck PJB; Coelho T; Waddington Cruz M; Brannagan TH; Khella S; Karam C; Berk JL; Polydefkis MJ; Kincaid JC; Wiesman JF; Litchy WJ; Mauermann ML; Ackermann EJ; Baker BF; Jung SW; Guthrie S; Pollock M; Dyck PJ
    Muscle Nerve; 2020 Oct; 62(4):509-515. PubMed ID: 32654156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis.
    Yu RZ; Collins JW; Hall S; Ackermann EJ; Geary RS; Monia BP; Henry SP; Wang Y
    Nucleic Acid Ther; 2020 Jun; 30(3):153-163. PubMed ID: 32286934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-life experience with inotersen at CEPARM, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro.
    Dias M; Pinto LF; Pinto MV; Gervais R; Accioli P; Amorim G; Guedes M; Gomes CP; Pedrosa RC; Waddington-Cruz M
    Arq Neuropsiquiatr; 2024 Apr; 82(4):1-7. PubMed ID: 38579737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform.
    Conceição I; Berk JL; Weiler M; Kowacs PA; Dasgupta NR; Khella S; Chao CC; Attarian S; Kwoh TJ; Jung SW; Chen J; Viney NJ; Yu RZ; Gertz M; Masri A; Cruz MW; Coelho T
    J Neurol; 2024 Aug; ():. PubMed ID: 39138650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.
    Nie T; Heo YA; Shirley M
    Drugs; 2023 Oct; 83(15):1425-1432. PubMed ID: 37728865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
    Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Gene therapy options for hereditary transthyretin-related amyloidosis].
    Schilling M
    Nervenarzt; 2022 Jun; 93(6):557-565. PubMed ID: 35419654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.
    Coelho T; Adams D; Conceição I; Waddington-Cruz M; Schmidt HH; Buades J; Campistol J; Berk JL; Polydefkis M; Wang JJ; Chen J; Sweetser MT; Gollob J; Suhr OB
    Orphanet J Rare Dis; 2020 Jul; 15(1):179. PubMed ID: 32641071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.
    Schmidt HH; Wixner J; Planté-Bordeneuve V; Muñoz-Beamud F; Lladó L; Gillmore JD; Mazzeo A; Li X; Arum S; Jay PY; Adams D;
    Am J Transplant; 2022 Jun; 22(6):1646-1657. PubMed ID: 35213769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity Assessment of Inotersen, a 2'-
    Yu RZ; Wang Y; Norris DA; Kim TW; Narayanan P; Geary RS; Monia BP; Henry SP
    Nucleic Acid Ther; 2020 Oct; 30(5):265-275. PubMed ID: 32833564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial.
    Quan D; Obici L; Berk JL; Ando Y; Aldinc E; White MT; Adams D
    Amyloid; 2023 Mar; 30(1):49-58. PubMed ID: 36120830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case of severe increase of liver enzymes in a ATTRv patient after one year of inotersen treatment.
    Severi D; Palumbo G; Spina E; Iovino A; Nolano M; Manganelli F; Tozza S
    Neurol Sci; 2023 Apr; 44(4):1419-1422. PubMed ID: 36576645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis.
    Mahfouz M; Maruyama R; Yokota T
    Methods Mol Biol; 2020; 2176():87-98. PubMed ID: 32865784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    Obici L; Berk JL; González-Duarte A; Coelho T; Gillmore J; Schmidt HH; Schilling M; Yamashita T; Labeyrie C; Brannagan TH; Ajroud-Driss S; Gorevic P; Kristen AV; Franklin J; Chen J; Sweetser MT; Wang JJ; Adams D
    Amyloid; 2020 Sep; 27(3):153-162. PubMed ID: 32131641
    [No Abstract]   [Full Text] [Related]  

  • 40. Focal Segmental Glomerulosclerosis Complicating Therapy With Inotersen, an Antisense Oligonucleotide Inhibitor: A Case Report.
    Law S; Arnold J; Rauf MU; Heptinstall L; Gilbertson J; Rowczenio D; Baharani J; Langman G; Fontana M; Gillmore JD
    Am J Kidney Dis; 2023 May; 81(5):606-610. PubMed ID: 36228827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.